Voting Results along with the Scrutiniser''s Report of the 36th AGM of the Company held on 23rd September 2025 through VC/OAVM.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals held its 36th Annual General Meeting on 23 September 2025 via video conferencing, where all 6 resolutions were passed with overwhelming shareholder support. Key items included approval of FY25 audited financial statements, reappointment of Dr. Shankarappa Nagaraja Vinaya Babu as Non-Executive Director, continuation of Mr. Pattamadai Natarajasarma Vijay as Independent Director (he will turn 75 during his term), appointment of Mr. Kashinath Sahu as Secretarial Auditor, and approval of material related party transactions for the company and its subsidiaries. Every resolution received over 99.98% approval, with opposition ranging from just 835 to 837 votes. Around 67.47% of outstanding shares participated in voting for the financial statements and director resolutions, while related party transaction resolutions saw only ~19.30% participation since the promoter group (1,712,417 shares) was barred from voting as an interested party.
All routine AGM business cleared with near-unanimous support, signalling no shareholder dissent on governance matters. Shareholders have pre-approved material related party transactions for the company and its subsidiaries, which investors should watch for execution details and arm's-length pricing in future filings.